US Patent

US8455527 — Methods of treatment using a dexmedetomidine premix formulation

Method of Use · Assigned to Hospira Inc · Expires 2032-01-04 · 6y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treatment using a premixed formulation of dexmedetomidine for parenteral administration in perioperative care or sedation.

USPTO Abstract

The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-421 — chembl-chembl2106195
U-421 — chembl-chembl2106195
U-421 — chembl-chembl2106195

Patent Metadata

Patent number
US8455527
Jurisdiction
US
Classification
Method of Use
Expires
2032-01-04
Drug substance claim
No
Drug product claim
No
Assignee
Hospira Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.